PE20070169A1 - Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1 - Google Patents
Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1Info
- Publication number
- PE20070169A1 PE20070169A1 PE2006000721A PE2006000721A PE20070169A1 PE 20070169 A1 PE20070169 A1 PE 20070169A1 PE 2006000721 A PE2006000721 A PE 2006000721A PE 2006000721 A PE2006000721 A PE 2006000721A PE 20070169 A1 PE20070169 A1 PE 20070169A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- alkyl
- pyrrol
- phenyl
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS DE 4,5-DIARIL-2-AMINOMETILPIRROL DE FORMULA (I), DONDE X ES -CO-, -SO2-, -CO-N(R6); R1 ES H O ALQUILO(C1-C4); R2 ES ALQUILO(C1-C12), CARBOCICLICO NO AROMATICO(C3-C12), METILO, FENILO, BENCILO, ENTRE OTROS OPCIONALMENTE SUSTITUIDOS; R3 ES ALQUILO(C1-C5) O CICLOALQUILO(C3-C7); R4 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS; R5 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4), CIANO, TRIFLUOROMETILO, ENTRE OTROS; R6 ES H O ALQUILO(C1-C4). SON PREFERIDOS: N-((5-(4-CLOROFENIL)-4-(2,4-DICLOROFENIL)-1-METIL-1H-PIRROL-2-IL)METIL-4-(TRIFLUOROMETIL)BENZAMIDA, 3-CLORO-N-((5-(4-CLOROFENIL)-4-(2,4-DICLOROFENIL)-1-METIL-1H-PIRROL-2-IL)METIL)-BENCENOSULFONAMIDA, N-((5-(4-CLOROFENIL)-4-(2,4-DICLOROFENIL)-1-METIL-1H-PIRROL-2-IL)METIL-N'-(3-TRIFLUOROMETIL)FENIL)UREA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES CB1 DE LOS CANABINOIDES LOCALIZADOS A NIVEL CENTRAL Y/O PERIFERICO Y SON UTILES PARA EL TRATAMIENTO DE TRANSTORNOS SIQUIATRICOS, COMO ANSIEDAD, DEPRESION, INSOMNIO, SICOSIS EN GENERAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0506609A FR2887548B1 (fr) | 2005-06-27 | 2005-06-27 | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070169A1 true PE20070169A1 (es) | 2007-03-07 |
Family
ID=35884019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000721A PE20070169A1 (es) | 2005-06-27 | 2006-06-23 | Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1 |
Country Status (28)
Country | Link |
---|---|
US (1) | US7618995B2 (es) |
EP (1) | EP1899298B1 (es) |
JP (1) | JP5142152B2 (es) |
KR (1) | KR20080019641A (es) |
CN (1) | CN101208300A (es) |
AR (1) | AR057401A1 (es) |
AT (1) | ATE478045T1 (es) |
AU (1) | AU2006263781A1 (es) |
BR (1) | BRPI0612497A2 (es) |
CA (1) | CA2610805A1 (es) |
CR (1) | CR9565A (es) |
DE (1) | DE602006016285D1 (es) |
DO (1) | DOP2006000133A (es) |
EA (1) | EA200800149A1 (es) |
EC (1) | ECSP078009A (es) |
FR (1) | FR2887548B1 (es) |
IL (1) | IL188032A0 (es) |
MA (1) | MA29559B1 (es) |
MX (1) | MX2007016383A (es) |
NO (1) | NO20080458L (es) |
NZ (1) | NZ564195A (es) |
PA (1) | PA8681701A1 (es) |
PE (1) | PE20070169A1 (es) |
SV (1) | SV2007002580A (es) |
TN (1) | TNSN07439A1 (es) |
TW (1) | TW200740753A (es) |
UY (1) | UY29631A1 (es) |
WO (1) | WO2007000505A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
BRPI0912539A2 (pt) * | 2008-05-05 | 2015-10-13 | Amgen Inc | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. |
FR2930939B1 (fr) * | 2008-05-09 | 2010-07-30 | Sanofi Aventis | Derives de pyrrole, leur preparation et leur application en therapeutique |
GB201103419D0 (es) | 2011-02-28 | 2011-04-13 | Univ Aberdeen | |
WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物 |
CH710832A1 (de) | 2015-03-09 | 2016-09-15 | Kaba Ag | Programmierbarer Schliesszylinder. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4335136A (en) * | 1980-04-18 | 1982-06-15 | E. I. Du Pont De Nemours And Company | Anti-inflammatory 4,5-diaryl-α-(polyfluoroalkyl)-1H-pyrrole-2-methanamines |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
ES2208964T3 (es) * | 1996-12-10 | 2004-06-16 | G.D. SEARLE & CO. | Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion. |
GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
-
2005
- 2005-06-27 FR FR0506609A patent/FR2887548B1/fr not_active Expired - Fee Related
-
2006
- 2006-06-12 DO DO2006000133A patent/DOP2006000133A/es unknown
- 2006-06-22 MX MX2007016383A patent/MX2007016383A/es not_active Application Discontinuation
- 2006-06-22 BR BRPI0612497-6A patent/BRPI0612497A2/pt not_active Application Discontinuation
- 2006-06-22 AT AT06764809T patent/ATE478045T1/de not_active IP Right Cessation
- 2006-06-22 JP JP2008518897A patent/JP5142152B2/ja not_active Expired - Fee Related
- 2006-06-22 CA CA002610805A patent/CA2610805A1/fr not_active Abandoned
- 2006-06-22 KR KR1020077030262A patent/KR20080019641A/ko not_active Application Discontinuation
- 2006-06-22 NZ NZ564195A patent/NZ564195A/en unknown
- 2006-06-22 WO PCT/FR2006/001416 patent/WO2007000505A2/fr active Application Filing
- 2006-06-22 PA PA20068681701A patent/PA8681701A1/es unknown
- 2006-06-22 EP EP06764809A patent/EP1899298B1/fr active Active
- 2006-06-22 CN CNA2006800230670A patent/CN101208300A/zh active Pending
- 2006-06-22 DE DE602006016285T patent/DE602006016285D1/de active Active
- 2006-06-22 AU AU2006263781A patent/AU2006263781A1/en not_active Abandoned
- 2006-06-22 EA EA200800149A patent/EA200800149A1/ru unknown
- 2006-06-23 SV SV2006002580A patent/SV2007002580A/es not_active Application Discontinuation
- 2006-06-23 PE PE2006000721A patent/PE20070169A1/es not_active Application Discontinuation
- 2006-06-23 AR ARP060102708A patent/AR057401A1/es unknown
- 2006-06-26 TW TW095122990A patent/TW200740753A/zh unknown
- 2006-06-27 UY UY29631A patent/UY29631A1/es unknown
-
2007
- 2007-11-26 TN TNP2007000439A patent/TNSN07439A1/en unknown
- 2007-12-06 CR CR9565A patent/CR9565A/es not_active Application Discontinuation
- 2007-12-07 US US11/952,224 patent/US7618995B2/en not_active Expired - Fee Related
- 2007-12-10 IL IL188032A patent/IL188032A0/en unknown
- 2007-12-13 EC EC2007008009A patent/ECSP078009A/es unknown
- 2007-12-24 MA MA30500A patent/MA29559B1/fr unknown
-
2008
- 2008-01-24 NO NO20080458A patent/NO20080458L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PA8681701A1 (es) | 2007-01-17 |
TNSN07439A1 (en) | 2009-03-17 |
EA200800149A1 (ru) | 2008-04-28 |
JP5142152B2 (ja) | 2013-02-13 |
CA2610805A1 (fr) | 2007-01-04 |
NZ564195A (en) | 2010-01-29 |
CR9565A (es) | 2008-04-10 |
US7618995B2 (en) | 2009-11-17 |
NO20080458L (no) | 2008-01-24 |
CN101208300A (zh) | 2008-06-25 |
EP1899298B1 (fr) | 2010-08-18 |
MX2007016383A (es) | 2008-03-07 |
AU2006263781A1 (en) | 2007-01-04 |
BRPI0612497A2 (pt) | 2010-11-23 |
EP1899298A2 (fr) | 2008-03-19 |
WO2007000505A2 (fr) | 2007-01-04 |
KR20080019641A (ko) | 2008-03-04 |
WO2007000505A3 (fr) | 2007-11-15 |
JP2008546829A (ja) | 2008-12-25 |
TW200740753A (en) | 2007-11-01 |
DE602006016285D1 (de) | 2010-09-30 |
DOP2006000133A (es) | 2007-02-28 |
FR2887548A1 (fr) | 2006-12-29 |
US20080176924A1 (en) | 2008-07-24 |
FR2887548B1 (fr) | 2007-09-21 |
IL188032A0 (en) | 2008-03-20 |
ATE478045T1 (de) | 2010-09-15 |
SV2007002580A (es) | 2007-02-19 |
MA29559B1 (fr) | 2008-06-02 |
AR057401A1 (es) | 2007-12-05 |
ECSP078009A (es) | 2008-01-23 |
UY29631A1 (es) | 2007-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
PE20090509A1 (es) | El uso de derivados de benzamida para el tratamiento de transtornos del snc | |
PE20070169A1 (es) | Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
PE20081530A1 (es) | Nuevos compuestos 617 | |
PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
PE20001483A1 (es) | Acidos oxamicos y derivados como ligandos de receptores tiroideos | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20040599A1 (es) | Amidas sustituidas como moduladores del receptor cannabinoide-1 (cb1) | |
PE20081314A1 (es) | COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB | |
PE20060632A1 (es) | Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a | |
AR052156A1 (es) | Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos | |
BRPI0507506A (pt) | compostos | |
PE20091431A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
PE20081755A1 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 | |
PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
PE20071224A1 (es) | Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1) | |
PE20060273A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3 | |
PE20091653A1 (es) | Derivados sustituidos de pirazol y su uso | |
PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |